Joseph Monahan - Feb 15, 2023 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: Chief Scientific Officer
Signature: /s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol: ACRS
Transactions as of: Feb 15, 2023
Transactions value $: -$65,311
Form type: 4
Date filed: 2/17/2023, 03:34 PM
Previous filing: Feb 3, 2023
Next filing: Mar 3, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Sale	-$65.3K	-5K	-5.19%	$13.06	91.4K	Feb 15, 2023	Direct	F1, F2
holding	ACRS	Common Stock						193	Feb 15, 2023	By Spouse

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022.
F2	The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.79 to $13.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022.

The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.79 to $13.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.